AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aquestive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.83+0.05 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $478.73M
- P/E (TTM)
- –
- Dividend yield
- –
Aquestive Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacture and supply revenue | $40.23M | $39.98M | $43.81M | $36.38M | $35.31M | $24.88M | $38.74M | $37.32M | $40.09M | 90.3% | +0.6% |
| License and royalty revenue (a) | $3.52M | $15.35M | $5.38M | $2.35M | $5.38M | $14.06M | $6.96M | $24.70M | $23.13M | 7.9% | -77.1% |
| Co-development and research fees | $1.28M | $1.93M | $1.40M | $1.29M | $1.64M | $1.26M | $4.04M | $5.18M | $3.69M | 2.9% | -33.6% |
| Royalty | $938.00K | $1.01M | $989.00K | -$916.00K | -$1.10M | – | – | – | – | 2.1% | -6.9% |
| Proprietary product revenue, net | -$478.00K | $315.00K | $0 | – | – | – | – | – | – | -1.1% | -251.7% |
| Proprietary product sales, net | – | – | $0 | $7.66M | $8.51M | $5.65M | $2.87M | $228.00K | $0 | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $29.60M | $39.93M | $37.10M | $40.79M | $42.86M | $40.96M | $48.29M | $64.57M | $63.71M | 66.5% | -25.9% |
| Ex-United States | $14.94M | $17.63M | $13.48M | $6.89M | $7.97M | $4.89M | $4.32M | $2.87M | – | 33.5% | -15.3% |
| Ex-United States [Member] | – | – | – | – | – | – | – | $2.87M | $3.21M | – | – |
From the segment and revenue-disaggregation notes of Aquestive Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.